Autism Disorder and Treatment Market Valued at USD 6.5 billion in 2023, projected to grow from USD 7.0 billion in 2024 to USD 12.21 billion by 2032, exhibiting a CAGR of 7.20% during the forecast period (2024 - 2032). Government Initiatives to Increase Awareness for the Disorder and Rising Prevalence of the Condition are the key market drivers enhancing the autism disorder and Treatment market growth.
Source Secondary Research, Primary Research, MRFR Database and Analyst Review
ASD, commonly referred to as autism spectrum disorder, is a set of neurological illnesses defined by a repetitive/restricted pattern of actions or activities and chronic deficiencies in interaction with others and social communication. The main factors anticipated to propel the market size for medicines for autism spectrum disorder throughout the forecast period are a growing incidence of the disease worldwide, increased awareness of the issue, and alternatives for treating various ailments. The development of the global market is additionally anticipated to be fueled by the leading players' increasing spending in R&D activities for the introduction of potent medications to treat autistic disorders. Furthermore, research aiming at better comprehending the causes of ASD is supported by funding from the National Institute of Neurological Disorders and Stroke (NINDS).
The construction and operation of neural synapses, which may not function as they should in individuals with neurodevelopmental and ASD problems, is one of the components of brain function and growth that the NINDS researchers investigate. The recent rise in the number of instances of autism spectrum disorder (ASD), which has driven up the demand for clinical research for effective treatment, is positively affecting the market expansion for autism disorder and treatment. Better results for patients and more accurate treatment for different ailments may result. Autism spectrum disorder is a chronic condition that impacts the sufferer and their family, friends, and communities. Every autistic kid or adult faces a unique mix of difficulties, and many people with the diagnosis also suffer from other illnesses like gastrointestinal (GI) problems.
Global market expansion is positively impacted by an increase in the overall incidence of autism spectrum disorder (ASD), which has increased the demand for clinical research for efficient treatment. This can improve patient outcomes and increase therapy accuracy for various disorders. Despite the growing demand for efficient clinical trials and medications for autism, there is currently no medication authorized to treat ASD. Some of the main barriers to research and drug development are knowledge shortages and complicated models in clinical translation research. The outcome of such an expansion of patient-centered initiatives would be early symptom diagnosis and faster market growth. In addition, it is projected that post-diagnosis demand for drugs to treat autism will support the market expansion of autism disorder and treatment.
In November 2021, a team of Indian researchers developed something called '6BIO' that can be used to treat Autism Spectrum Disorder (ASD) in a better way. This is the first compound in preclinical clinical evaluation that has demonstrated potential for enhancing daily activities, such as the ability to learn new tasks as well as remember them again among ASD/ ID patients.
Further, Axial Therapeutics raised $37 million Series C funding for phase II autism research in October 2021, concerning neurologic disorders like autism spectrum.
In April 2022, XRHealth announced its gateway to metaverse healthcare where they said that it was now possible to have their virtual/augmented reality therapy available in the United States to children with autism. The above will see an influx of drugs development thereby adding value to market growth.
The market expansion of Autism Disorder and Treatment is being favourably impacted by an increase in the prevalence of autism spectrum disorder (ASD), which has increased need for clinical research for efficient treatment. This can lead to better patient outcomes and more precise therapy for various illnesses. For instance, France and Portugal have the lowest rates of autism in the world, with 0.69% and 0.71%, respectively, according to a research published on the subject by Health Data Exchange. In contrast, it has been observed that the majority of Middle Eastern nations, including Qatar, the United Arab Emirates, Oman, Bahrain, and Saudi Arabia, have the greatest prevalence of the illness. For instance, it is predicted that Qatar would have a 1.6% prevalence of autism in 2021 while Saudi Arabia will have a 1.0% prevalence. Due to the rising need for potent medications, it is also projected that the prevalence rate in developing nations would continue to rise. The introduction of potent medications is also projected to result in better patient results, supporting the market's development prospects for the treatment of autism spectrum condition.
Figure 1 Autism prevalence Since 2000
Secondary Research, Primary Research, MRFR Database and Analyst Review
The market of Autism Disorder and Treatment is anticipated to be driven by extensive research studies carried out by organisations to assess the efficacy and safety of medications in patients with ASD. The excellent findings of these investigations present the market with fresh chances for expansion. For instance, Stalicla completed successfully phase 1b trials of precision medicine candidate STP1 in March 2022, and the findings were encouraging with symptom reduction in ASD patients. Therefore, it is projected that the trial's successful conclusion and following product approvals will boost the Autism Disorder and Treatment market growth.
The Autism Disorder and Treatment market is expanding as a result of a rising number of government efforts, such as the creation of various foundations and the approval of various financing for autism awareness campaigns in various nations. The Saskatchewan government's initiatives are only a few of the government-led campaigns to raise autism awareness throughout the world.The Saskatchewan government stated in July 2021 that families with children who have the condition will get access to increased financing. For kids 11 and under, autism-specific funding will be available starting on July 27, 2021. The last payment was only available to children who were born on or before March 31, 2021. Additionally, USD 10.3 million was allocated in 2021–2022 to provide USD 6,000.0 yearly to kids with ASD between the ages of 6 and 11 years.
Such an increase in patient-centered efforts would eventually result in early symptom detection and accelerate market growth. In addition, after-diagnosis demand for medications to treat autism is anticipated to support the market expansion of Autism Disorder and Treatment .
The Autism Disorder and Treatment market segmentation, based on type, includes autistic, Asperger Syndrome, Pervasive Developmental Disorder. The autistic disorder segment held a dominant market share of Autism Disorder and Treatment in the year 2021 owing to the high prevalence of this disease type. The segment held a 54.3% market share in 2021 and is projected to expand at a considerably high CAGR during the forecast period. According to Pfizer’s report, 1 of every 6 to 8-year-old children are affected by autistic disorder. Therefore, the demand for effective treatment availability is the need of the hour. Hence, pharmaceutical companies are striving to get approvals for products for the management of the disorder and reducing the disease burden on the industry.
Figure 2 Autism Disorder and Treatment Market, by type, 2024 & 2032 (USD Million)
Secondary Research, Primary Research, MRFR Database and Analyst Review
The Autism Disorder and Treatment market segmentation, based on Treatment type, includes Aplied Behavior Analysis (ABA), Hyperbaric Oxygen Therapy, and Others. Communication and Behavioral Therapy is at the leading position in today's market and will remain on the top during the forecast period.
The market segments of autism disorder and treatment, based on Drug, includes SSRIs, Anti-Convulsant, Others. The stimulants segment held a dominating Autism Disorder and Treatment market share in 2021 in the market due to increased focus and decreased hyperactivity in people with autism and is projected to expand at a considerably high CAGR during the forecast period. Stimulants particularly contribute to a substantial increase in the core symptoms of autism. The SSRIs/antidepressants segment held the second dominant share, as it is the most commonly prescribed class of drug to autistic people. SSRIs like sertraline help reduce the intensity and frequency of autism-related behaviors like repetitive actions, anxiety, irritability, tantrums, and aggressive actions. This segment is expected to expand at a considerably high CAGR during the forecast period.
News:A pharmacologist at Vanderbilt University Medical Center and his group will pave the way for possible remedies for schizophrenia and autism spectrum disorder (ASD) with the help of a four-year, $2.7 million research grant from the National Institute of Mental Health, a division of the National Institutes of Health (NIH). Both ASD and schizophrenia have higher ratios of excitatory-to-inhibitory synaptic transmission. The study focuses on a class of inhibitory neurons termed GABAergic interneurons, which link different brain parts and are essential for coordinating high-frequency brain activity. The excitatory/inhibitory imbalance seen in ASD and schizophrenia may be caused by failure of the potassium channel Kv3.1, which is exclusive to GABAergic interneurons.
By Region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. North America Autism Disorder and Treatment market accounted largest share and is expected to exhibit a significant CAGR growth during the study period. North America dominated the overall market owing to the launch and rapid uptake of multiple ASD drugs. Increasing research activities in the region in the field of ASD are projected to open new growth opportunities in the region. For instance, in January 2020, F. Hoffmann-La Roche Ltd. initiated a clinical trial study on a new experimental product Balovaptan for people with ASD in Toronto, Canada. Successful completion of the study is expected to fuel Autism Disorder and Treatment market growth.
Further, the major countries studied in the market report are The U.S, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Figure 3 AUTISM DISORDER AND TREATMENT MARKET SHARE BY REGION 2021 (%)
Secondary Research, Primary Research, MRFR Database and Analyst Review
Increasing awareness and screening, access to aid, and broadened diagnostic criteria have made Europe the second largest region in the market. Further, higher product sales are anticipated to boost the market in the region during the forecast period. Further, the Germany market of Autism Disorder and Treatment held the largest market share, and the UK market of Autism Disorder and Treatment was the fastest growing market in the European region.
Asia Pacific is expected to register a lucrative growth rate of 7.6% over the forecast period. The growth of the region is attributed to the presence of key players in the market of Autism Disorder and Treatment and strategic initiatives undertaken by them to develop and commercialize new products to treat patients. For instance, in May 2022, Teijin Pharma and Hamamatsu Medical University among others confirmed the safety, efficacy, and tolerability of oxytocin nasal spray to treat patients with autism spectrum disorder. This collaboration boosts the research and development of novel ASD drugs in the Asia Pacific region.
Autism Disorder and Treatment Key Market Players & Competitive Insights
Major market players are spending a lot of money on R&D to increase their product lines, which will help the in the market growth of Autism Disorder and Treatment even more. Market participants are also taking a range of strategic initiatives to grow their worldwide footprint, with key market developments such as new product launches, contractual agreements, mergers and acquisitions, increased investments, and collaboration with other organizations. Competitors in the Autism Disorder and Treatment industry must offer cost-effective items to expand and survive in an increasingly competitive and rising market environment.
One of the primary business strategies adopted by manufacturers in the Autism Disorder and Treatment industry to benefit clients and expand the market sector is to manufacture locally to reduce operating costs. In recent years, Autism Disorder and Treatment industry has provided medicine with some of the most significant benefits. The Autism Disorder and Treatment market major player such as Medtronic Inc (Ireland), Abbott Laboratories (US), Stryker Corporation (US), and others are working to expand the industry demand by investing in research and development activities.
Hoffmann-La Roche AG, commonly known as Roche, is a Swiss multinational healthcare company that operates worldwide under two divisions Pharmaceuticals and Diagnostics. The company controls the American biotechnology company Genentech, which is a wholly owned affiliate, and the Japanese biotechnology company Chugai Pharmaceuticals, as well as the United States-based companies Ventana and Foundation Medicine. In December 2021 F. Hoffmann-La Roche Ltd drug pipeline candidate of RO7017773 was in an ongoing trial phase 2 trial to investigate the efficacy, safety, and tolerability in participants aged 15-45 years with autism spectrum disorder (ASD). The company plans for a regulatory filing in 2024.
Axial Therapeutics is a biopharmaceutical company targeting neurological disorders such as Parkinson's and Autism via gut health. In October 2021 Axial Therapeutics announced that the company received clearance from the U.S. Food and Drug Administration (FDA) of its Investigational New Drug (IND) application for their lead candidate named AB-2004, which is a gut-targeted, molecular therapeutic being studied for the treatment of irritability associated with ASD.
Key Companies in the Autism Disorder and Treatment market includes
Autism Disorder and Treatment Industry Developments
| Report Attribute/Metric | Details |
| Market Size 2023 | USD 6.5 billion |
| Market Size 2024 | USD 6.96 billion |
| Market Size 2032 | USD 12.20 billion |
| Compound Annual Growth Rate (CAGR) | 7.2% (2024-2032) |
| Base Year | 2023 |
| Market Forecast Period | 2024-2032 |
| Historical Data | 2018 & 2020 |
| Market Forecast Units | Value (USD Billion) |
| Report Coverage | Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Product Type, Operating Platforms, and Region |
| Geographies Covered | North America, Europe, Asia Pacific, and Rest of the World |
| Countries Covered | The U.S, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil |
| Key Companies Profiled | Pfizer Inc.Eli Lilly and Company, Allergan, Merck & CO Inc., Teva Pharmaceutical Industries Ltd., Concern Pharma Private Limited, Novartis AG, Johnson & Johnson ServicesInc., Bristol-Myers Squibb, Otsuka Holdings Co. |
| Key Market Opportunities | Rising Prevalence of the Condition to Propel Market Growth |
| Key Market Dynamics | Government Initiatives to Increase Awareness for the Disorder to Boost Market Growth Rising Prevalence of the Condition to Propel Market Growth |
Autism Disorder and Treatment Market Highlights:
Frequently Asked Questions (FAQ) :
The Autism Disorder and Treatment market size was valued at USD 6.5 Billion in 2023.
The market for Autism Disorder and Treatment is projected to grow at a CAGR of 7.2% during the forecast period, 2024-2032.
North America had the largest share in the Autism Disorder and Treatment market
The key players in the Autism Disorder and Treatment market are Pfizer Inc.Eli Lilly and Company, Allergan, Merck & CO Inc., Teva Pharmaceutical Industries Ltd., Concern Pharma Private Limited, Novartis AG, Johnson & Johnson ServicesInc., Bristol-Myers Squibb, Otsuka Holdings Co.
The Autistic Autism Disorder and Treatment category dominated the market in 2021.
The Communication and Behavioral Therapy had the largest share in the Autism Disorder and Treatment market.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
Research Analyst Level I He is an extremely curious individual currently working in healthcare and medical devices domain. kinjoll is comfortably versed in data centric research backed by healthcare educational background. he leverages extensive data mining and analytics tools such as primary and secondary research, statistical analysis, machine learning, data modelling. his key role also involves technical sales support, client interaction and project management within the healthcare team. lastly, he showcases extensive affinity towards learning new skills and remain fascinated in implementing them.
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
